İlaca Bağlı Olarak Çene Kemiklerinde Görülen Osteonekrozda Dental Yönetim ve Güncel Tedavi Yaklaşımları: Derleme

Ayşem Yurtseven Günay; Gülsüm Ak

Review

Dental Management in Medication-Related Osteonecrosis of the Jaws and Current Treatment Approachs: Review

Year 2020, Volume: 3 Issue: 2, 81 - 92, 10.07.2020

Ayşem Yurtseven Günay , Gülsüm Ak

Abstract

Today, antiresorptive and antiangiogenic drugs are used in the treatment of breast, prostate or lung cancer, hypercalcemia, multiple myeloma or osteolytic metastatic lesions. In addition to these diseases, they can also be used in the treatment of osteoporosis. Depending on the use of these drugs, osteonecrosis may occur in the maxilla and mandible. In this review, we aimed to provide information about the etiology, risk factors, clinical course, radiological features, current treatment protocols and dental approach of the osteonecrosis that develops due to drug use in the jaws

Keywords

References

1. Valente NA, Chatelain S, Alfonsi F, Mortellaro C, Barone A. Medication-related osteonecrosis of the jaw. J Craniofac Surg 2019;30:1095–101. doi:10.1097/SCS.0000000000005475
2. Yazıcı T, Şentürk MF, Koçer G. İlaca bağlı olarak çene kemiklerinde görülen osteonekroz (Mronj):Derleme. SDÜ Sağlık Bil Enst Derg 2017;8(2):50-7. doi:10.22312/sdusbed.302041
3. Değim T. Bifosfonatlar ve çene kemiğinde kemik erimesi. Ecza Derg 2006;13: 26-8.
4. Walter C, Al-Nawas B, Grötz KA, Thomas C, Thüroff JW, Zinser V, et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008;54:1066–72. doi:10.1016/j.eururo.2008.06.070
5. Walter C, Al-Nawas B, du Bois A, Buch L, Harter P, Grötz KA. Incidence of bisphosphonateassociated osteonecrosis of the jaws in breast cancer patients. Cancer 2009;115:1631–37. doi:10.1002/cncr.24119
6. Van Poznak C, Estilo C. Osteonecrosis of the jaw in cancer patients receiving iv bisphosphonates. Oncology 2006;20(9):1053–62.
7. Delmas PD, Recker RR, Chesnut CH 3rd, Skag A, Stakkestad JA, Emkey R, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: Results from the bone study. Osteoporos Int 2004;15:792–8. doi:10.1007/s00198-004-1602-9
8. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007;29:1548–58. doi:10.1016/j.clinthera.2007.08.008
9. Siris ES, Lyles KW, Singer FR, Meunier PJ. Medical management of Paget’s disease of bone: Indications for treatment and review of current therapies. J Bone Miner Res 2006;21:94–8. doi:10.1359/jbmr.06s218
10. Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, et al. Long-term control of bone turnover in Paget’s disease with zoledronic acid and risedronate. J Bone Miner Res 2007;22:142– 8. doi:10.1359/jbmr.061001
11. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet 2004;363:1377–85. doi:10.1016/S01406736(04)16051-0
12. Kamoun-Goldrat A, Ginisty D, Merrer ML. Effect of bisphosphonates on tooth eruption in children with osteogenesis imperfecta. Eur J Oral Sci 2008;116:195–8. doi: 10.1111/j.16000722.2008.00529.x
13. Duman AE, Güven GS, Gürlek A. Erkek osteoporozu. Hacettepe Tıp Derg 2005;36:175–83.
14. Marx RE. Palmidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7. doi:10.1016/ s0278-2391(03)00720-1
15. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62:527–34. doi:10.1016/j.joms.2004.02.004
16. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 2011;377:813–22. doi:10.1016/S0140-6736(10)62344-6
17. Reszka AA, Rodan GA. Mechanism of action of bisphosphonates. Curr Osteoporos Rep 2003;1:45–52. doi: 10.1007/s11914-003-0008-5
18. Reszka AA, Rodan GA. Nitrogencontaining bisphosphonate mechanism of action, Mini Rev Med Chem 2004;4:711–9. doi:10.2174/1389557043403648
19. Stepensky D, Kleinberg L, Hoffman A. Bone as an effect compartment: models for uptake and release of drugs. Clin Pharmacokinet 2003;42:863–81. doi:10.2165/00003088-200342100-00001
20. Naidu A, Dechow PC, Spears R, Wright JM, Kessler HP, Opperman LA. The effects of bisphosphonates on osteoblasts in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;106:5–13. doi:10.1016/j.tripleo.2008.03.036
21. Favia G, Pilolli GP, Maiorano E. Histologic and histomorphometric features of bisphosphonaterelated osteonecrosis of the jaws: An analysis of 31 cases with confocal laser scanning microscopy. Bone 2009;45(3):406–13. doi:10.1016/j. bone.2009.05.008
22. Hinson AM, Smith CW, Siegel ER, Stack BC Jr. Is bisphosphonate-related osteonecrosis of the jaw an infection? A histological and microbiological ten-year summary. Int J Dent 2014;2014:452737. doi:10.1155/2014/452737
23. Soydan SS, Veziroğlu Şenel F, Araz K. Bifosfonata bağlı olarak çene kemiklerinde gelişen osteonekrozun patogenezi ve tedavisi. Hacettepe Diş Hek Fak Derg 2009;33(3):61-8.
24. Gupta M, Gupta N. Bisphosphonate Related Jaw Osteonecrosis. [Updated 2019 Sep 19]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-.
25. Aghaloo T, Hazboun R, Tetradis S. Pathophysiology of osteonecrosis of the jaws. Oral Maxillofac Surg Clin North Am 2015;27(4):48996. doi:10.1016/j.coms.2015.06.001 2
6. Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 2008;66(5):839–47. doi:10.1016/j.joms.2008.01.026
27. Scoletta M, Arduino PG, Dalmasso P, Broccoletti R, Mozzati M. Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;110(1):46– 53. doi:10.1016/j.tripleo.2010.02.020
28. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws [published correction appears in Ann Intern Med. 2006 Aug 1;145(3):235]. Ann Intern Med 2006;144(10):753–61. doi:10.7326/0003-4819144-10-200605160-00009
29. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63(11):1567–75. doi:10.1016/j.joms.2005.07.010
30. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353(1):99–102. doi:10.1056/ NEJM200507073530120
31. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23(34):8580–7. doi:10.1200/ JCO.2005.02.8670
32. Zavras AI, Zhu S. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis?. J Oral Maxillofac Surg 2006;64(6):917–23. doi:10.1016/j.joms.2006.02.011
33. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medicationrelated osteonecrosis of the jaw--2014 update [published correction appears in J Oral Maxillofac Surg. 2015 Jul;73(7):1440] [published correction appears in J Oral Maxillofac Surg. 2015 Sep;73(9):1879]. J Oral Maxillofac Surg 2014;72(10):1938–56. doi:10.1016/j.joms.2014.04.031
34. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded activecontrolled phase III trials in cancer patients with bone metastases. Ann Oncol 2012; 23(5): 1341– 7. doi: 10.1093/annonc/mdr435
35. Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 2013; 14(9): 901-8. doi: 10.1016/S14702045(13)70277-8
36. Colella G, Campisi G, Fusco V. American Association of Oral and Maxillofacial Surgeons position paper: Bisphosphonate-Related Osteonecrosis of the Jaws-2009 update: the need to refine the BRONJ definition. J Oral Maxillofac Surg 2009;67(12):2698–9. doi:10.1016/j. joms.2009.07.097
37. Vassiliou V, Tselis N, Kardamakis D. Osteonecrosis of the jaws: clinicopathologic and radiologic characteristics, preventive and therapeutic strategies. Strahlenther Onkol 2010;186(7):367– 73. doi:10.1007/s00066-010-2066-9
38. Stockmann P, Hinkmann FM, Lell MM, Fenner M, Vairaktaris E, Neukam FW, et al. Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study. Clin Oral Investig 2010;14(3):311–7. doi:10.1007/s00784-009-0293-1
39. Dore F, Filippi L, Biasotto M, Chiandussi S, Cavalli F, Di Lenarda R. Bone scintigraphy and SPECT/ CT of bisphosphonate-induced osteonecrosis of the jaw. J Nucl Med 2009;50(1):30–5. doi:10.2967/ jnumed.107.048785
40. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102(4):433–41. doi:10.1016/j.tripleo.2006.06.004
41. Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006;134(6):620–3. doi:10.1111/j.1365-2141.2006.06230.x
42. Campisi G, Di Fede O, Musciotto A, Lo Casto A, Lo Muzio L, Fulfaro F, et al. Bisphosphonate related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis. Ann Oncol 2007;18(6):168–72. doi:10.1093/annonc/mdm250
43. Hino S, Murase R, Terakado N, Shintani S, Hamakawa H. Response of diffuse sclerosing osteomyelitis of the mandible to alendronate: follow-up study by 99mTc scintigraphy. Int J Oral Maxillofac Surg 2005;34(5):576–8. doi:10.1016/j. ijom.2005.01.003
44. van der Waal RI, Buter J, van der Waal I. Oral metastases: report of 24 cases. Br J Oral Maxillofac Surg 2003;41(1):3–6. doi:10.1016/ s0266-4356(02)00301-7
45. Marx RE. Oral and intravenous bisphosphonate induced osteonecrosis of the jaws: history, etiology, prevention, and treatment. 2nd ed. Quintessence Pub Co; 2011.
46. Karaçelebi E, Öztürk M. Oral ve maksillofasial cerrahide bifosfonatlar ve bifosfonatlar ilişkili çene osteonekrozu tedavisinde yeni yaklaşımlar. ADO Klin Bil Derg 2012(5): 1052–62.
47. Perini AT, de Oliveira GR, Seguin F. Medicationrelated osteonecrosis of the jaw (MRONJ) treated with piezosurgery – case report and review of literature. RSBO 2018;15(2):123-9. doi: 10.21726/rsbo.v15i2.679
48. Merigo E, Cella L, Oppici A, Cristina Arbasi M, Clini F, Fontana M, et al. Combined Approach to Treat Medication-Related Osteonecrosis of the Jaws. J Lasers Med Sci 2018;9(2):92-100. doi: 10.15171/jlms.2018.19.
49. Phal PM, Myall RW, Assael LA, Weissman JL. Imaging findings of bisphosphonate-associated osteonecrosis of the jaws. Am J Neuroradiol 2007;28:1139–45. doi: 10.3174/ajnr.A0518
50. Berg BI, Mueller AA, Augello M, Berg S, Jaquiéry C. Imaging in Patients with BisphosphonateAssociated Osteonecrosis of the Jaws (MRONJ). Dent J (Basel) 2016;4(3):29. doi:10.3390/dj4030029
51. Rosella D, Papi P, Giardino R, Cicalini E, Piccoli L, Pompa G. Medication-related osteonecrosis of the jaw: Clinical and practical guidelines. J Int Soc Prev Community Dent 2016;6(2):97‐104. doi:10.4103/2231-0762.178742
52. Di Fede O, Panzarella V, Mauceri R, Fusco V, Bedogni A, Lo Muzio L, et al. The dental management of patients at risk of medication-related osteonecrosis of the jaw: new paradigm of primary prevention. Biomed Res Int 2018;2018:2684924. doi: 10.1155/2018/2684924.
53. Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, et al. MedicationRelated Osteonecrosis of the Jaw: MASCC/ ISOO/ASCO Clinical Practice Guideline. J Clin Oncol 2019;37(25):2270–90. doi:10.1200/ JCO.19.01186
54. Öztürk E, Saruhan N. İlaca bağlı olarak çene kemiklerinde görülen osteonekroz (Mronj): Derleme. J BHSR 2019;3(1):8-20. doi: 10.34084/ bshr.535974
55. Favia G, Piattelli A, Sportelli P, Capodiferro S, Iezzi G. Osteonecrosis of the posterior mandible after implant insertion: a clinical and histological case report. Clin Implant Dent Relat Res 2011;13(1):58–63. doi:10.1111/j.17088208.2009.00181.x
56. Lazarovici TS, Yahalom R, Taicher S, SchwartzArad D, Peleg O, Yarom N. Bisphosphonaterelated osteonecrosis of the jaw associated with dental implants. J Oral Maxillofac Surg 2010;68(4):790–6. doi:10.1016/j. joms.2009.09.017
57. Shirota T, Nakamura A, Matsui Y, Hatori M, Nakamura M, Shintani S. Bisphosphonaterelated osteonecrosis of the jaw around dental implants in the maxilla: report of a case. Clin Oral Implants Res 2009;20(12):1402–8. doi:10.1111/j.1600-0501.2009.01801.x
58. Walter C, Al-Nawas B, Wolff T, Schiegnitz E, Grötz KA. Dental implants in patients treated with antiresorptive medication - a systematic literature review. Int J Implant Dent 2016;2(1):9. doi:10.1186/s40729-016-0041-7
59. Freiberger JJ, Padilla-Burgos R, McGraw T, Suliman HB, Kraft KH, Stolp BW, et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. J Oral Maxillofac Surg 2012;70(7):1573–83. doi:10.1016/j.joms.2012.04.001
60. Adornato MC, Morcos I, Rozanski J. The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors. J Am Dent Assoc 2007;138(7):971–7. doi:10.14219/ jada.archive.2007.0294
61. Erkan M, Bilgi O, Mutluoğlu M, Uzun G. Bisphosphonate-related osteonecrosis of the jaw in cancer patients and hyperbaric oxygen therapy. JOP 2009;10(5):579–82.
62. Momesso GAC, de Souza Batista FR, de Sousa CA, de Lima VN, Polo TOB, Hassumi JS, et al. Successful use of lower-level laser therapy in the treatment of medication-related osteonecrosis of the jaw. J Lasers Med Sci 2017;8(4):201–3. doi:10.15171/jlms.2017.37
63. Sarkarat F, Modarresi A, Chiniforush N, Yazdanparast L, Rakhshan V. Efficacy of photodynamic therapy in minimizing bisphosphonate-related osteonecrosis of the jaws after dental extraction: A preliminary animal study. J Oral Maxillofac Surg 2019;77(2):307–14. doi:10.1016/j.joms.2018.09.036
64. Cicciù M, Herford AS, Juodžbalys G, Stoffella E. Recombinant human bone morphogenetic protein type 2 application for a possible treatment of bisphosphonates-related osteonecrosis of the jaw. J Craniofac Surg 2012;23(3):784–8. doi:10.1097/SCS.0b013e31824dbdd4
65. Curi MM, Cossolin GS, Koga DH, Zardetto C, Christianini S, Feher O, et al. Bisphosphonaterelated osteonecrosis of the jaws-an initial case series report of treatment combining partial bone resection and autologous platelet-rich plasma. J Oral Maxillofac Surg 2011;69(9):2465– 72. doi:10.1016/j.joms.2011.02.078
66. Epstein MS, Wicknick FW, Epstein JB, Berenson JR, Gorsky M. Management of bisphosphonateassociated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;110(5):593–6. doi:10.1016/j.tripleo.2010.05.067